

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparin Pharmaceutical Group Co., Ltd. (the **Company**) regarding the bid for the acquisition of the **Group** (the **Inside Information**) pursuant to the provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (**Listing Rules**).

The board of directors (the **Directors**) of the Company (the **Board**) in the light of the shareholder of the Company (the **Shareholders**) and the relationship with Techdow Pharma Italia S.R.L., a wholly owned subsidiary of the Company (**Techdow Italy**), is pleased to have been defined as a **Confidential** disclosure of the **Incident**. The Company has issued the **Incident** to the **Shareholders** of the Company. The **Shareholders** are advised to file a **Confidential** disclosure of the **Incident** to the **Shareholders** of the Company. The **Shareholders** are advised to file a **Confidential** disclosure of the **Incident** to the **Shareholders** of the Company.

The **Shareholders** of the Company have been advised by the **Board** of the Company to file a **Confidential** disclosure of the **Incident** to the **Shareholders** of the Company. The **Shareholders** are advised to file a **Confidential** disclosure of the **Incident** to the **Shareholders** of the Company. The **Shareholders** are advised to file a **Confidential** disclosure of the **Incident** to the **Shareholders** of the Company.

The independent members of the Company's Board of Directors, including the Independent Non-executive Directors, have reviewed the financial statements and the related information of the Company for the period from January 1, 2023 to December 31, 2023 (FY2023).

The Company's independent non-executive directors have reviewed the financial statements and the related information of the Company for the period from January 1, 2023 to December 31, 2023 (FY2023).

The Board of Directors has reviewed the financial statements of the Company for the period from January 1, 2023 to December 31, 2023 (FY2023).

The Company will make the annual general meeting of the shareholders to discuss the financial statements and the related information of the Company for the period from January 1, 2023 to December 31, 2023 (FY2023 Annual Results), which is expected to be held in March 2024, in accordance with the provisions of the Company's Articles of Association and the Listing Rules, and the related financial statements will be published in the Annual Report.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
January 15, 2024

As a reminder of his announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yi and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. L. Chan, Mr. Hang Peng and Mr. Yi Ming.